|
|
ASCO Avastin Alone Shows Edge in Recurrent Gl
http//wwwmedpagetodaycom
J Leonard Lichtenfeld, MD, American Cancer Society
CHICAGO -- For refractory glioblastoma, second-line bevacizumab (Avastin) as monotherapy has been associated with a 28 response rate and an overall survival edge, albeit nonsignificant, over the agent plus irinotecan (Campt Tags : health medicine Views : 152 This video added by MedPageToday .
|
|
|
|
|